A 9‐yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult‐type ADA deficiency
暂无分享,去创建一个
P. Ind | B. Bax | R. Chalmers | L. Fairbanks | Bridget E Bax | Murray D Bain | Lynette D Fairbanks | A David B Webster | Philip W Ind | Michael S Hershfield | Ronald A Chalmers | A. Webster | M. Hershfield | M. Bain | B. E. Bax | Lynette D. Fairbanks | Philip W. Ind | Michael S. Hershfield
[1] F. Rosen,et al. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. , 1981, The Journal of clinical investigation.
[2] R. Hirschhorn. Adenosine deaminase deficiency: molecular basis and recent developments. , 1995, Clinical immunology and immunopathology.
[3] A. O'Hagan,et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. , 2006, Health technology assessment.
[4] J. Hughes,et al. Adult presentation of adenosine deaminase deficiency , 1993, The Lancet.
[5] R. Chalmers. Comparison and potential of hypo-osmotic and iso-osmotic erythrocyte ghosts and carrier erythrocytes as drug and enzyme carriers. , 1985, Bibliotheca haematologica.
[6] R. Aspinall,et al. Both age and gender affect thymic output: more recent thymic migrants in females than males as they age , 2001, Clinical and experimental immunology.
[7] H. Gaspar,et al. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. , 2001, The Journal of pediatrics.
[8] J. Hughes,et al. Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. , 1994, Journal of immunology.
[9] M. Hershfield. Biochemistry and Immunology of Poly(ethylene glycol)-Modified Adenosine Deaminase (PEG-ADA) , 1997 .
[10] H. Simmonds,et al. Carrier erythrocyte entrapped adenosine deaminase therapy in adenosine deaminase deficiency. , 2000, Advances in experimental medicine and biology.
[11] B. Bax,et al. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol‐conjugated and native adenosine deaminase , 2000, British journal of haematology.
[12] A. Aiuti. Gene therapy for adenosine-deaminase-deficient severe combined immunodeficiency. , 2004, Best practice & research. Clinical haematology.
[13] R H Glew,et al. Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[14] Louis J. Picker,et al. Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.
[15] K. Weinberg,et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). , 2005, Clinical immunology.
[16] R. Hirschhorn. Overview of Biochemical Abnormalities and Molecular Genetics of Adenosine Deaminase Deficiency , 1993, Pediatric Research.
[17] A. Aguzzi,et al. Adenosine deaminase deficiency in adults. , 1997, Blood.
[18] L. Notarangelo,et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). , 2007, Clinical immunology.
[19] M. Hershfield,et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. , 1992, The Journal of clinical investigation.
[20] B. Bax,et al. Survival of human carrier erythrocytes in vivo. , 1999, Clinical science.
[21] R. Kobayashi,et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. , 1987, The New England journal of medicine.
[22] A. Mortellaro,et al. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.
[23] C. Shovlin. Glaxo/MRS Young Investigator Medal. Molecular studies on adenosine deaminase deficiency and hereditary haemorrhagic telangiectasia. , 1998, Clinical science.
[24] U. Pannicke,et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. , 2007, Blood.
[25] L. Notarangelo,et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol‐adenosine deaminase‐treated patients , 2005, European journal of immunology.